RE:RE:COVID and the risk of lung diseasesTencents wrote: Many studies confirm severe case Covid 19 can lead to such lung conditions
whats changed is the number of incidents - this makes the market potential significantly lower than pandemic conditions would givr
funds don't go easily to low patients numbers
The risk rises with reinfection and the virus is still everywhere. The virus continues to mutate. One infection, two infections, three infections, on and on. The next ten years could be catastrophic given the burden of disease and that there is no preventative for fibrosis. COVID wasn't around when Avalyn raised its C$80 million going into Phase I testing and PGX-YBG can be used outside the lungs too and as a delivery platform for treating other diseases.
"Fourthly, our study showed a significant increase of the long-term risk of developing asthma, COPD, ILD, and lung cancer diseases among individuals who suffered SARS-CoV-2 reinfection. This finding emphasizes the importance of preventing reinfection of COVID-19 in order to protect public health and reduce the potential burden of SARS-CoV-2 reinfection. By identifying specific diseases with higher long-term risks in reinfected individuals, heightened awareness and tailored prevention and treatment strategies can be implemented in a targeted manner for those at risk." The Lancet
Dr. Kolb: "We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice. If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University." May 2023